SG Americas Securities’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.4M | Sell |
82,966
-6,722
| -7% | -$94.1K | ﹤0.01% | 1679 |
|
|
2026
Q1 | $1.15M | Buy |
89,688
+16,545
| +23% | +$211K | ﹤0.01% | 1675 |
|
|
2025
Q4 | $658K | Sell |
73,143
-57,927
| -44% | -$797K | ﹤0.01% | 2330 |
|
|
2025
Q3 | $2.26M | Buy |
131,070
+92,485
| +240% | +$1.14M | 0.01% | 882 |
|
|
2025
Q2 | $362K | Sell |
38,585
-2,852
| -7% | -$23.4K | ﹤0.01% | 1875 |
|
|
2025
Q1 | $295K | Sell |
41,437
-3,401
| -8% | -$34.4K | ﹤0.01% | 2221 |
|
|
2024
Q4 | $523K | Buy |
44,838
+20,694
| +86% | +$323K | ﹤0.01% | 1305 |
|
|
2024
Q3 | $496K | Buy |
24,144
+17,947
| +290% | +$414K | ﹤0.01% | 1696 |
|
|
2024
Q2 | $139K | Buy |
6,197
+366
| +6% | +$8.71K | ﹤0.01% | 2363 |
|
|
2024
Q1 | $160K | Buy |
+5,831
| New | +$162K | ﹤0.01% | 2148 |
|
|
2023
Q3 | – | Sell |
-9,552
| Closed | -$390K | – | 3208 |
|
|
2023
Q2 | $390K | Sell |
9,552
-10,627
| -53% | -$431K | ﹤0.01% | 1516 |
|
|
2023
Q1 | $752K | Buy |
20,179
+219
| +1% | +$8.59K | 0.01% | 1385 |
|
|
2022
Q4 | $696K | Buy |
19,960
+9,078
| +83% | +$432K | 0.01% | 1251 |
|
|
2022
Q3 | $609K | Buy |
10,882
+3,863
| +55% | +$240K | 0.01% | 1368 |
|
|
2022
Q2 | $363K | Sell |
7,019
-14,814
| -68% | -$752K | ﹤0.01% | 2231 |
|
|
2022
Q1 | $1.59M | Sell |
21,833
-10,017
| -31% | -$849K | 0.01% | 1080 |
|
|
2021
Q4 | $3.77M | Buy |
31,850
+17,323
| +119% | +$2.17M | 0.02% | 634 |
|
|
2021
Q3 | $1.95M | Buy |
14,527
+4,440
| +44% | +$672K | 0.01% | 1291 |
|
|
2021
Q2 | $1.63M | Sell |
10,087
-1,199
| -11% | -$93.4K | 0.01% | 1246 |
|
|
2021
Q1 | $906K | Buy |
11,286
+5,149
| +84% | +$346K | ﹤0.01% | 1620 |
|
|
2020
Q4 | $334K | Sell |
6,137
-33,460
| -85% | -$1.22M | ﹤0.01% | 2291 |
|
|
2020
Q3 | $787K | Buy |
39,597
+5,170
| +15% | +$108K | 0.01% | 1335 |
|
|
2020
Q2 | $724K | Buy |
+34,427
| New | +$585K | 0.01% | 1735 |
|
|
2019
Q1 | – | Sell |
-8,239
| Closed | -$112K | – | 3536 |
|
|
2018
Q4 | $112K | Buy |
+8,239
| New | +$153K | ﹤0.01% | 2677 |
|
|
2018
Q2 | – | Sell |
-42,960
| Closed | -$906K | – | 3484 |
|
|
2018
Q1 | $906K | Buy |
+42,960
| New | +$1.06M | 0.01% | 1426 |
|
|
2017
Q4 | – | Sell |
-10,169
| Closed | -$253K | – | 3485 |
|
|
2017
Q3 | $253K | Buy |
10,169
+3,863
| +61% | +$72.8K | ﹤0.01% | 2388 |
|
|
2017
Q2 | $101K | Buy |
+6,306
| New | +$88.1K | ﹤0.01% | 2917 |
|
|
2017
Q1 | – | Sell |
-36,794
| Closed | -$482K | – | 3485 |
|
|
2016
Q4 | $482K | Buy |
36,794
+9,979
| +37% | +$150K | ﹤0.01% | 1723 |
|
|
2016
Q3 | $456K | Buy |
26,815
+9,306
| +53% | +$180K | ﹤0.01% | 1783 |
|
|
2016
Q2 | $374K | Buy |
+17,509
| New | +$466K | ﹤0.01% | 1848 |
|
Other funds holding NTLA
AIM
RCM
RP
SG Americas Securities's NTLA Position: Q2 2026 in Review
SG Americas Securities reduced its Intellia Therapeutics (NTLA) stake by 7.5% in Q2 2026, selling an estimated $94.1K and leaving 82,966 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1679.
SG Americas Securities first reported a position in NTLA in Q2 2016 and has held it in 30 quarters since. The position peaked at $3.77M in Q4 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- SG Americas Securities held 82,966 shares of Intellia Therapeutics worth $1.4M as of Q2 2026.
- SG Americas Securities sold 6,722 Intellia Therapeutics shares in Q2 2026, an estimated $94.1K.
- Intellia Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1679 holding.
- SG Americas Securities first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 30 quarters since.
- SG Americas Securities's Intellia Therapeutics position peaked at $3.77M in Q4 2021.
- 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.